Great Novel Therapeutics Biotech & Medicals Corp.(TW:7427)
NT$59.50+-0.50 (+2.23%)
TW:7427
Great Novel Therapeutics Biotech & Medicals Corp. financials statements
NT$59.50
At close:+-0.50 (+2.23%)
Great Novel Therapeutics Biotech & Medicals Corp. (7427) Ratios
Great Novel Therapeutics Biotech & Medicals Corp. Ratios
TW:7427's free cash flow for Q2 2026 was NT$0.00. For the 2026 fiscal year, TW:7427's free cash flow was increased by NT$50.03M and operating cash flow was NT$-50.03M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 24.12 | 27.43 | 30.47 | 20.87 | 5.80 |
| Quick Ratio | 23.74 | 27.30 | 30.08 | 20.87 | 5.80 |
| Cash Ratio | 1.54 | 7.11 | 11.27 | 9.22 | 2.91 |
| Solvency Ratio | -3.78 | -3.35 | -2.13 | -4.48 | -1.59 |
| Operating Cash Flow Ratio | -4.54 | -3.52 | -3.45 | -5.46 | -1.57 |
| Short-Term Operating Cash Flow Coverage | -25.70 | -718.21 | -88.27 | -79.01 | -39.44 |
| Net Current Asset Value | NT$ 442.68M | NT$ 569.42M | NT$ 458.64M | NT$ 239.41M | NT$ 103.80M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.02 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.05 | 1.04 | 1.03 | 1.10 |
| Debt Service Coverage Ratio | -26.13 | -421.82 | -79.98 | -64.77 | -40.79 |
| Interest Coverage Ratio | -1026.23 | -901.18 | -723.30 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.18 | 0.26 | 0.40 | 0.03 | 0.04 |
| Net Debt to EBITDA | 0.24 | 1.48 | 2.89 | 2.04 | 1.77 |
| Profitability Margins | |||||
| Gross Profit Margin | -735.93% | 60.24% | 99.11% | 85.93% | 44.92% |
| EBIT Margin | -8260.91% | -6219.53% | -1266.99% | -10329.44% | -5796.98% |
| EBITDA Margin | -7623.24% | -5807.83% | -1177.46% | -9992.04% | -5568.10% |
| Operating Profit Margin | -8260.91% | -6685.28% | -1357.11% | -10636.67% | -5796.98% |
| Pretax Profit Margin | -8089.05% | -6226.94% | -1268.87% | -10329.44% | -5691.59% |
| Net Profit Margin | -8089.05% | -6226.94% | -1268.87% | -10329.44% | -5691.59% |
| Continuous Operations Profit Margin | -8089.05% | -6226.94% | -1257.67% | -10329.44% | -5691.59% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.92% | 93.14% | 93.50% | 97.11% | 98.18% |
| Return on Assets (ROA) | -18.50% | -15.84% | -9.54% | -14.96% | -15.59% |
| Return on Equity (ROE) | -19.38% | -16.57% | -9.96% | -15.46% | -17.21% |
| Return on Capital Employed (ROCE) | -19.62% | -17.58% | -10.47% | -15.92% | -17.53% |
| Return on Invested Capital (ROIC) | -19.49% | -17.50% | -10.41% | -15.88% | -17.46% |
| Return on Tangible Assets | -19.51% | -16.52% | -11.57% | -20.40% | -25.37% |
| Earnings Yield | -7.08% | -7.49% | -2.53% | -4.08% | -4.68% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.49 | 1.21 | 8.60 | 5.24 | 9.13 |
| Payables Turnover | 0.00 | 0.00 | 0.07 | 0.00 | 0.40 |
| Inventory Turnover | 1.38 | 0.22 | 0.01 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.12 | 0.12 | 0.30 | 4.66 | 5.34 |
| Asset Turnover | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 |
| Cash Conversion Cycle | 509.39 | 1942.08 | 47051.05 | 69.62 | -864.63 |
| Days of Sales Outstanding | 245.05 | 300.66 | 42.45 | 69.62 | 39.98 |
| Days of Inventory Outstanding | 264.34 | 1641.41 | 52296.86 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 5288.26 | 0.00 | 904.61 |
| Operating Cycle | 509.39 | 1942.08 | 52339.31 | 69.62 | 39.98 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.94 | -1.86 | -1.52 | -2.73 | -1.61 |
| Free Cash Flow Per Share | -1.94 | -1.95 | -1.60 | -3.25 | -2.94 |
| Dividend Paid and CapEx Coverage Ratio | -313.74 | -22.19 | -18.80 | -5.23 | -1.21 |
| Capital Expenditure Coverage Ratio | -313.74 | -22.19 | -18.80 | -5.23 | -1.21 |
| Operating Cash Flow Coverage Ratio | -11.19 | -7.34 | -3.83 | -79.01 | -39.44 |
| Operating Cash Flow to Sales Ratio | -72.90 | -45.61 | -11.34 | -121.88 | -53.84 |
| Free Cash Flow Yield | -6.40% | -5.73% | -2.38% | -5.73% | -8.08% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -14.13 | -13.33 | -39.41 | -24.51 | -21.38 |
| Price-to-Sales (P/S) Ratio | 1143.21 | 831.72 | 501.23 | 2531.98 | 1216.57 |
| Price-to-Book (P/B) Ratio | 2.74 | 2.21 | 3.93 | 3.79 | 3.68 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -15.63 | -17.45 | -41.97 | -17.44 | -12.38 |
| Price-to-Operating Cash Flow Ratio | -15.68 | -18.24 | -44.20 | -20.77 | -22.60 |
| Price-to-Earnings Growth (PEG) Ratio | 0.90 | -0.27 | 1.49 | -0.68 | 1.56 |
| Enterprise Value Multiple | -14.76 | -12.84 | -39.68 | -23.30 | -20.08 |
| Enterprise Value | 1.36B | 1.26B | 2.27B | 1.26B | 704.51M |
| EV to EBITDA | -14.76 | -12.84 | -39.68 | -23.30 | -20.08 |
| EV to Sales | 1124.96 | 745.91 | 467.17 | 2327.82 | 1118.27 |
| EV to Free Cash Flow | -15.38 | -15.65 | -39.12 | -16.04 | -11.38 |
| EV to Operating Cash Flow | -15.43 | -16.36 | -41.20 | -19.10 | -20.77 |
| Tangible Book Value Per Share | 10.50 | 14.70 | 13.93 | 10.82 | 5.68 |
| Shareholders’ Equity Per Share | 11.10 | 15.36 | 17.03 | 14.94 | 9.88 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.03 | 0.04 | 0.13 | 0.02 | 0.03 |
| Net Income Per Share | -2.15 | -2.55 | -1.70 | -2.31 | -1.70 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.98 | 1.00 | 1.00 | 1.00 | 0.98 |
| Research & Development to Revenue | 56.79 | 50.50 | 10.95 | 71.36 | 30.33 |
| SG&A to Revenue | 18.46 | 16.96 | 3.61 | 35.87 | 28.09 |
| Stock-Based Compensation to Revenue | 9.26 | 8.88 | 2.33 | 9.10 | 5.81 |
| Income Quality | 0.90 | 0.73 | 0.90 | 1.18 | 0.95 |
Currency in TWD
